MD Medical Group MDMG ANNOUNCEMENT OF EXERCISE OF OVER-ALLOTMENT OPTION

  MD Medical Group (MDMG) - ANNOUNCEMENT OF EXERCISE OF OVER-ALLOTMENT OPTION

RNS Number : 8250Q
MD Medical Group Investments PLC
09 November 2012


THIS  PRESS  RELEASE  AND  THE   INFORMATION  CONTAINED  HEREIN  IS  NOT   FOR 
PUBLICATION, DISTRIBUTION OR RELEASE IN, OR INTO, DIRECTLY OR INDIRECTLY,  THE 
UNITED STATES OF AMERICA (INCLUDING ITS TERRITORIES AND POSSESSIONS),  CANADA, 
JAPAN OR AUSTRALIA  OR TO ANY  OTHER JURISDICTION WHERE  SUCH AN  ANNOUNCEMENT 
WOULD BE UNLAWFUL.  THE INFORMATION  CONTAINED HEREIN DOES  NOT CONSTITUTE  AN 
OFFER OF SECURITIES FOR SALE IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN.



This press release is, for UK regulatory purposes, an advertisement and not  a 
prospectus and investors should not  subscribe for or purchase any  securities 
referred to in this press  release except on the  basis of information in  the 
prospectus published by MD Medical  Group Investments Plc. This press  release 
does not constitute or form part of any offer or invitation to sell or  issue, 
or any solicitation of any offer to  purchase or subscribe for, any shares  or 
other securities of MD Medical Group Investments Plc, nor shall any part of it
nor the fact of its  distribution form part of or  be relied on in  connection 
with any  contract  or  investment  decision relating  thereto,  nor  does  it 
constitute a  recommendation  regarding the  securities  of MD  Medical  Group 
Investments Plc.





                               MD MEDICAL GROUP

              ANNOUNCEMENT OF EXERCISE OF OVER-ALLOTMENT OPTION



9 November 2012 - MD Medical  Group Investments Plc ("MD Medical Group",  LSE: 
MDMG), Russia's leading provider of private women's and children's healthcare,
today announces  that in  connection  with its  initial public  offering  (the 
"Offering") the over-allotment option granted  by MD Medical Holding  Limited, 
the selling  shareholder,  has been  exercised  by the  Joint  Bookrunners  in 
respect of 1,564,066 ordinary shares in the form of global depositary receipts
("GDRs"), representing 6.94% of the base offer size.



The offering of shares in the form of  GDRs was priced on 12 October at  US$12 
per GDR  with one  GDR representing  an interest  in one  ordinary share.  The 
over-allotment shares were sold at the offer price.



The  total   Offering   size,   including  the   over-allotment   option,   is 
US$289,218,828comprising 24,101,569  GDRs.  Following  the  exercise  of  the 
over-allotment option, MD  Medical Group's  free float  will be  approximately 
32.1%.





For further information, contact:



MD Medical Group

Andrey Braginskiy (Investors)

Tel: +7 985 211 7478

ir@mospmc.ru



Anastasia Anichenkova (Media)

Tel: +7 495 332 6670 / +7 916 661 6242

a.anichenkova@mospmc.ru



M:Communications

Tom Blackwell / Anna Yarmarkova - Moscow

Tel: +7 495 363 2846

mdmg@mcomgroup.com



Sarah Macleod / Mary-Jane Elliott - London

Tel: +44 20 7920 2300

mdmg@mcomgroup.com













IMPORTANT NOTICE



This press-release does  not constitute  or form part  of, and  should not  be 
construed as, an offer of securities to the public in the United Kingdom,  nor 
is it intended to be  an inducement to engage  in investment activity for  the 
purpose of  Section 21  of the  Financial Services  and Markets  Act 2000  (as 
amended) of the United Kingdom  ("FSMA"). Consequently, this press-release  is 
only being distributed to and is directed only at (i) persons who are  outside 
the United Kingdom or (ii) persons who have professional experience in matters
relating to investments  falling within the  meaning of Article  19(5) of  the 
Financial Services and Markets Act 2000 (Financial Promotion) Order 2005  (the 
"FP Order"), (iii) high net worth entities falling within Article 49(2)(a)-(d)
of the FP Order and (iv) other persons to whom it may lawfully be communicated
(all such  persons together  being referred  to as  "relevant persons").  Any 
investment activity to which this press-release relates will only be available
to, and will only be engaged with, relevant persons. Any person who is not  a 
relevant person  should  not act  or  rely on  this  document or  any  of  its 
contents.



This press-release is  not an  offer to  sell nor  a solicitation  to buy  any 
securities  nor  a  prospectus  for   the  purposes  of  applicable   measures 
implementing EU Directive 2003/71/EC  as may be amended  from time to time.  A 
prospectus has been prepared and is available to the public in accordance with
Directive 2003/71/EC (together  with any applicable  implementing measures  in 
any Member State, the "Prospectus Directive"). Investors should not  subscribe 
for or purchase any securities referred to in this press release except on the
basis of the information  contained in the prospectus  to be published by  the 
Company in due course relating to the securities.





This press-release do not  constitute a public offer  or advertisement of  any 
securities in  the Russian  Federation, an  offer, or  an invitation  to  make 
offers, to purchase, sell, exchange or transfer any securities in the  Russian 
Federation or to the benefit  of any Russian person  and do not constitute  an 
"advertisement" or  "offering" of  the securities  in the  Russian  Federation 
within the meaning of  Russian securities laws  and must not  be passed on  to 
third  parties  or  otherwise  be  made  publicly  available  in  the  Russian 
Federation. No prospectus will be registered with respect to these  securities 
in the  Russian Federation  and  the securities  referred  to herein  are  not 
intended  for,  "offering",  "placement"  or  "circulation"  in  the   Russian 
Federation unless otherwise permitted under Russian law.



The information contained herein does not  constitute an offer to sell or  the 
solicitation of an offer to buy, nor shall there be any sale of the securities
referred to herein in  any jurisdiction in which  such offer, solicitation  or 
sale would be unlawful prior  to registration, exemption from registration  or 
qualification under the securities laws of any such jurisdiction.



Some of the information in this press release may contain projections or other
forward‐looking statements  regarding future  events.  The Company  wishes  to 
caution you that these statements are only predictions and that actual  events 
or results may differ materially. The Company does not intend to update  these 
statements to reflect events and circumstances occurring after the date hereof
or to reflect the occurrence of unanticipated events.



Not for publication, distribution or release  in the United States of  America 
(including its territories and possessions), Canada, Japan or Australia.



In connection with the offering, Deutsche Bank AG, London Branch or any  agent 
or other person acting on  its behalf may over-allot GDRs  up to a maximum  of 
3,380,624 additional GDRs  or effect other  stabilisation transactions with  a 
view to supporting the market  price of the GDRs at  a level higher than  that 
which  might  otherwise  prevail  in  the  open  market.  Such   stabilisation 
activities may be effected on any securities market, over-the-counter  market, 
stock exchange  or otherwise  and may  be undertaken  at any  time during  the 
period commencing  on the  date of  the announcement  of the  offer price  and 
ending no later than  30 calendar days thereafter.  However, there will be  no 
obligation on Deutsche Bank AG, London Branch  or any of its agents to  effect 
stabilising transactions,  and  there can  be  no assurance  that  stabilising 
transactions will  be  undertaken.  Such stabilising,  if  commenced,  may  be 
discontinued at any time  without prior notice. In  no event will measures  be 
taken to stabilise the market price of the GDRs above the offer price.



Save as required by  law or regulation, Deutsche  Bank AG, London Branch  does 
not  intend  to  disclose  the  extent  of  any  over-allotments  made  and/or 
stabilisation transactions conducted in relation to the offering.

                     This information is provided by RNS
           The company news service from the London Stock Exchange

END


MSCDKLFBLFFXFBF -0- Nov/09/2012 17:34 GMT
 
Press spacebar to pause and continue. Press esc to stop.